Search

Marine macroalgae have a very high carbohydrate content due to complex algal polysaccharides (APS) like agar, alginate, and ulvan in their cell wall. Despite numerous reports on their biomedical properties, their hydrocolloid nature limits their applications. Algal oligosaccharides (AOS), which are hydrolyzed forms of complex APS, are gaining importance due to their low molecular weight, biocompatibility, bioactivities, safety, and solubility in water that makes it a lucrative alternative. The AOS produced through enzymatic hydrolysis using microbial enzymes have far-reaching applications because of its stereospecific nature. Identification and characterization of novel microorganisms producing APS hydrolyzing enzymes are the major bottlenecks for the efficient production of AOS. This review will discuss the marine microbial enzymes identified for AOS production and the bioactive potential of enzymatically produced AOS. This can improve our understanding of the biotechnological potential of microbial enzymes for the production of AOS and facilitate the sustainable utilization of algal biomass. Enzymatically produced AOS are shown to have bioactivities such as antioxidant, antiglycemic, prebiotic, immunomodulation, antiobesity or antihypercholesterolemia, anti-inflammatory, anticancer, and antimicrobial activity. The myriad of health benefits provided by the AOS is the need of the hour as there is an alarming increase in physiological disorders among a wide range of the global population., (© 2022. Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i.)

Global requirement for algal foods is increasing, as they are progressively consumed for its nutrition and health. Macroalgae is a proven source of metabolites, proteins, pigments, bioactive compounds, and algal polysaccharides. The unique polysaccharides such as agar, carrageenan, porphyran, alginate, fucoidan, laminarin, and ulvan are known for its wide range of bioactivities and extensively used for applications from tissue engineering to drug delivery. However, there are few limitations due to its high molecular size, low compatibility, and hydrocolloid nature. Hence, the enzymatically produced algal oligosaccharides have drawn tremendous attention due to its green synthesis, solubility, and lower molecular size. They are reported to have bioactivities including antioxidant, antiglycemic, immunostimulatory, anti-inflammatory, and prebiotic activities, which can be used in the healthcare and nutraceutical industry for the manufacture of functional foods and dietary supplements. However, identification of potential microorganisms, producing polysaccharide hydrolyzing enzymes, remains a major bottle neck for efficient utilization of bioactive algal oligosaccharides. This review summarizes the recent developments in the identification and characterization of microbial enzymes for the production of bioactive algal oligosaccharides. This can improve our understanding of bioactive algal oligosaccharides and pave way for efficient utilization of macroalgae to prevent various chronic diseases.

Aims: To characterize the polysaccharide hydrolyzing potential of macroalgae‐associated bacteria (MABs) for the enzymatic production of oligosaccharides and determining their prebiotic potential. Methods and Results: Approximately 400 MABs were qualitatively characterized for polysaccharide hydrolyzing activity. Only about 5%–15% of the isolates were found to have the potential for producing porphyranase, alginate lyase and ulvan lyase enzymes, which were quantified in specific substrate broths. One potential MAB, Bacillus subtilis, NIOA181, isolated from green macroalgae, showed the highest ulvan lyase activity. This enzyme was partially purified and used to hydrolyse ulvan into ulvan oligosaccharides. Structural characterization of ulvan oligosaccharides showed that they are predominantly composed of di‐, tri‐ and tetrasaccharide units. Results showed that the enzymatically produced ulvan oligosaccharides exhibited prebiotic activity by promoting the growth of probiotic bacteria and suppressing the enteric pathogens, which were higher than the ulvan polysaccharide and equivalent to commercial fructooligosaccharides. Conclusions: A potential MAB, NIOA181, producing ulvan lyase was isolated and used for the production of ulvan oligosaccharides with prebiotic activity. Significance and Impact of the Study: Rarely studied ulvan oligosaccharides with prebiotic activity can be widely used as an active pharmaceutical ingredient in nutraceutical and other healthcare applications. [ABSTRACT FROM AUTHOR]